Oncology Evolved

Engineering the Next Generation of Off-the-Shelf Cell Therapies

PIPELINE

PRE-CLINICAL

CLINICAL

CAR-T (Allogeneic)

T-ALL/LBL

WU-CART-007

Memory NK (Allogeneic)

AML

WU-NK-101

Solid Tumors

WU-NK-101 + mAb

Solid Tumors

WU-NK-201 Engineered

LATEST NEWS

Wugen to Present Data on WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023

-- Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance --…

Read more
Wugen Announces CEO Transition

-- Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer -- ST. LOUIS, MO and SAN DIEGO, CA, March…

Read more
Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium

-- WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors -- --WU-NK-101 exhibited robust trafficking, intra-tumor infiltration,…

Read more
OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

Radio Button Off
About Wugen

Wugen is a clinical-stage biotechnology company

Flask
Science

Cellular therapies originating from healthy donors

People
Careers

Come join our growing teams in San Diego and St. Louis